Loading
Latest filing published 27 May 2022 for Ensysce Biosciences, Inc., €13k.
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Lynn Kirkpatrick, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Ensysce Biosciences, Inc. and Cascadian Therapeutics, Inc. In total, 5 filings cover trades dated from 10 December 2007 to 26 May 2022.
Every open-market trade on record is a purchase: 2 purchases worth €45k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant. Since January 2022: 2 purchases and no sales on the market.
The newest entry dates from 27 May 2022: an open-market purchase of €13k, in Ensysce Biosciences, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations